This comes partly from unsatisfactory response rates after usual treatment, highlighting the need for early indicators such as early improvement of depressive symptoms to adapt treatment strategies, especially for severe inpatients.
The treatment of migraine headache is challenging given the lack of a standardized approach to care, unsatisfactory response rates, and medication overuse.
Several studies have described GPs' CAM views [ 14] and practices [ 15]; however, most of them have been hampered by methodological problems such as small sample size, convenience sampling, or unsatisfactory response rates [ 16].
However, the efficacy of doxorubicin in the treatment of NSCLC remains unsatisfactory with a response rate of 15% [42].
The conventional treatment options for advanced gastric patients remain unsatisfactory in terms of response rate, response duration, toxicity, and overall survival benefit.
Platinum doublet chemotherapy is the major treatment for advanced non-small-cell lung cancer (NSCLC), but the outcome is still unsatisfactory, with an objective response rate of 30%40%% and a median survival time of 8 10 months [ 2].
Moreover, the prognosis of patients with advanced or unresectable HCC remains unsatisfactory due to a low response rate and short time to progression.
However, the efficacy of such treatments have remained largely unsatisfactory, with reported response rates in unselected NSCLC patients that had been treated previously being 6.7 10.8% with docetaxel (Shepherd et al, 2000), 9.1% with pemetrexed (Hanna et al, 2004), and 8.9% with erlotinib (Shepherd et al, 2005).
Briefly, ADA was administered to 6,610 patients with active RA (defined as 28-joint Disease Activity Score (DAS28) based on erythrocyte sedimentation rate (ESR) ≥3.2 and an unsatisfactory response to at least one synthetic DMARD).
Overall, the activity of doxorubicin (DOXO) is unsatisfactory, whereas, the analogous epidoxorubicin (EPI) yields a 30% response rate (RR) when administered at intermediate-high doses.
Despite the progress made with recent clinical use of anti-cytokine biologics, the response rate of rheumatoid arthritis treatment remains unsatisfactory, owing largely to the complexity of cytokine interactions and the multiplicity of cytokine targets.
